SEARCH

SEARCH BY CITATION

Keywords:

  • drug reaction;
  • melanoma;
  • panniculitis;
  • vemurafenib

Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation. Recently, four patients have been described in the literature who developed a neutrophilic panniculitis following treatment with a BRAF inhibitor. We present an additional case and review the clinical findings of the cases reported to date.